Yoo Hee Jun, Ham Chang Hwa, Roh Haewon, Jo Hyun Jun, Kwon Woo Keun, Yoon Wonki, Kim Jong Hyun, Kwon Taek Hyun, Byun Joonho
Department of Neurosurgery, Chung Ang University Gwangmyung Hospital, Chung Ang University College of Medicine, Seoul, Korea.
Department of Neurosurgery, Korea University Guro Hospital, Korea University Medical College, Seoul, Korea.
Neurosurg Rev. 2025 Jan 28;48(1):93. doi: 10.1007/s10143-025-03238-1.
Craniopharyngiomas are challenging benign tumors arising from Rathke's pouch remnants, often requiring multidisciplinary management due to their proximity to critical neurovascular structures. This meta-analysis systematically compares conventional radiation therapy (RT) and stereotactic radiosurgery (RS) in treating residual or recurrent craniopharyngiomas.
A comprehensive literature search identified 44 studies, including 46 reports, meeting inclusion criteria such as progression-free survival (PFS) and post-radiotherapy complications. Data extraction followed PRISMA guidelines.
The pooled 5-year PFS favored RT (0.843; 95% CI: 0.767-0.898) over RS (0.680; 95% CI: 0.631-0.727), as did 10-year PFS (RT: 0.813; 95% CI: 0.683-0.888; RS: 0.553; 95% CI: 0.470-0.634). RT demonstrated mitigating tumor recurrence risks. Visual and hormonal complication rates between the modalities were comparable (visual: ~4%; hormonal: ~6%).
RT consistently achieved superior long-term PFS compared to RS, reaffirming its role as the standard for adjuvant therapy in craniopharyngiomas. This analysis highlights the need for tailored treatment strategies balancing efficacy and safety, ultimately enhancing patient outcomes.
颅咽管瘤是起源于拉克氏囊残余的具有挑战性的良性肿瘤,由于其靠近关键神经血管结构,通常需要多学科管理。这项荟萃分析系统地比较了传统放射治疗(RT)和立体定向放射外科治疗(RS)在治疗残余或复发性颅咽管瘤方面的效果。
通过全面的文献检索确定了44项研究,包括46份报告,这些研究符合无进展生存期(PFS)和放疗后并发症等纳入标准。数据提取遵循PRISMA指南。
汇总的5年无进展生存期显示,放射治疗(0.843;95%可信区间:0.767 - 0.898)优于立体定向放射外科治疗(0.680;95%可信区间:0.631 - 0.727),10年无进展生存期也是如此(放射治疗:0.813;95%可信区间:0.683 - 0.888;立体定向放射外科治疗:0.553;95%可信区间:0.470 - 0.634)。放射治疗显示出降低肿瘤复发风险的作用。两种治疗方式之间的视觉和激素并发症发生率相当(视觉:约4%;激素:约6%)。
与立体定向放射外科治疗相比,放射治疗始终能实现更优的长期无进展生存期,再次确认了其作为颅咽管瘤辅助治疗标准的地位。该分析强调了需要制定平衡疗效和安全性的个性化治疗策略,最终改善患者预后。